|
|
Article: StressGen, Roche Deal Worth Up To $204M For HPV Drug.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
StressGen Biotechnologies Corp. found a partner for its lead drug to treat the human papilloma virus, nailing down a deal worth up to $204 million in milestone payments with F. Hoffmann-La Roche Ltd., which includes a $5 million equity investment and an undisclosed up-front payment on signing the deal.
The milestones "are equally distributed" in the near term and far term, said Daniel Korpolinski, president and CEO of Victoria, British Columbia-based StressGen. About 20 percent would come in the first two years, one-half during the remaining development period up to launch, and a third within five years after that, he told BioWorld ...
Related newspaper, magazine, and journal articles:
|
|
Article: Stressgen announces third quarter 2002 financial results ...
PR Newswire;
October 10, 2002 ;
700+ words
... ... call will include: Daniel L. Korpolinski, President and CEO; Donald ... our recent partnership with Roche," said Daniel L. Korpolinski, President and Chief Executive ... Collaboration Agreement with Roche for the co-development and ...
|
|